Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rexahn Pharmaceuticals has received European patent no. EP1212055 from the European Patent Office (EPO).
Subscribe to our email newsletter
The new patent named, ‘Neurotherapeutic compositions comprising a beta-lactam compound,’ includes compounds including clavulanic acid and moxalactam as a treatment for neurological disorders like, Alzheimer’s disease, anxiety, dementia, Parkinson’s disease and depression.
The patent also covers the use and pharmaceutical formulation of those compounds.
Rexahn president Rick Soni said obtaining this European patent coverage for clavulanic acid and moxalactam broadens and strengthens their CNS-related portfolio, which includes Serdaxin, currently in Phase II clinical trials.